Background: Systemic lupus erythematosus (SLE), a chronic multiorgan systemic autoimmune disease, damages and inflames numerous organs. Interleukin-17 (IL-17) is involved in lupus, its levels are often high in SLE patients. The Fc gamma receptor (FcRs) is crucial for immune system regulation and for allowing communication between humoral and cellular immune responses. Objective: In this study, the blood levels of IL-17 and FcR in people with lupus erythematosus were examined, and their relationships with various clinical manifestations, disease activity, and laboratory results were assessed. Patients and methods: 100 SLE patients who satisfied the diagnostic criteria for the disease in September 2019 from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) . All of them proceeded to the Sohag University Hospital's outpatient clinic or inpatient unit, where they had comprehensive clinical and medical examinations as well as standard laboratory tests including ANA, anti-dsDNA, C3,C4, and urine albumin creatinine.IL 17 & FcR ELISA assay and renal biopsies are further tests. Results: IL-17 was significantly different between mild, moderate and severe SLE with (p <0.05). FcγR had significant positive correlation with Systemic Lupus Erythematosus (P<0.05). The results of the analysis for the predicted probability of combined biomarkers in discerning moderate/severe from mild cases of SLE are highly significant, indicates that the combined biomarkers have a very high level of accuracy in distinguishing between these two groups. Conclusion: IL17 and FcγR had significant positive correlation with SLE activity indicating their role in activity of SLE.